amphotericin b

Summary

Summary: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.

Top Publications

  1. ncbi Amphotericin B and its new derivatives - mode of action
    M Baginski
    Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology, Poland
    Curr Drug Metab 10:459-69. 2009
  2. ncbi Leishmaniasis
    B L Herwaldt
    Centers for Disease Control and Prevention, Division of Parasitic Diseases, Atlanta, GA 30341 3724, USA
    Lancet 354:1191-9. 1999
  3. ncbi Antifungal effect of various essential oils against Candida albicans. Potentiation of antifungal action of amphotericin B by essential oil from Thymus vulgaris
    R Giordani
    Laboratoire de Botanique, Cryptogamie et Biologie Cellulaire, Faculte de Pharmacie, Universite de la Mediterranee, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France
    Phytother Res 18:990-5. 2004
  4. pmc Liposomal amphotericin B as a treatment for human leishmaniasis
    Manica Balasegaram
    Drugs for Neglected Diseases Initiative, Geneva, Switzerland
    Expert Opin Emerg Drugs 17:493-510. 2012
  5. pmc Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India
    Prabhat K Sinha
    Rajendra Memorial Research Institute of Medical Science, Patna, Bihar, India
    Am J Trop Med Hyg 83:357-64. 2010
  6. ncbi Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence
    Koert Ritmeijer
    Public Health Department, Medecins Sans Frontieres, Amsterdam, The Netherlands
    Clin Infect Dis 53:e152-8. 2011
  7. ncbi Combination therapy for visceral leishmaniasis
    Johan van Griensven
    Department of Clinical Sciences, Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium
    Lancet Infect Dis 10:184-94. 2010
  8. ncbi Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
    Annemarie E Brouwer
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 363:1764-7. 2004
  9. ncbi Drug resistance in Indian visceral leishmaniasis
    S Sundar
    Kala Azar Medical Research Centre, Banaras Hindu University, Varanasi, India
    Trop Med Int Health 6:849-54. 2001
  10. pmc Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial
    Joseph N Jarvis
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa
    AIDS 26:1105-13. 2012

Detail Information

Publications360 found, 100 shown here

  1. ncbi Amphotericin B and its new derivatives - mode of action
    M Baginski
    Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology, Poland
    Curr Drug Metab 10:459-69. 2009
    b>Amphotericin B (AmB) is a well known antifungal and antiprotozoal antibiotic used in the clinic for several decades...
  2. ncbi Leishmaniasis
    B L Herwaldt
    Centers for Disease Control and Prevention, Division of Parasitic Diseases, Atlanta, GA 30341 3724, USA
    Lancet 354:1191-9. 1999
    ..compounds have been the mainstay of antileishmanial therapy for half a century, but lipid formulations of amphotericin B (though expensive and administered parenterally) represent a major advance for treating visceral leishmaniasis...
  3. ncbi Antifungal effect of various essential oils against Candida albicans. Potentiation of antifungal action of amphotericin B by essential oil from Thymus vulgaris
    R Giordani
    Laboratoire de Botanique, Cryptogamie et Biologie Cellulaire, Faculte de Pharmacie, Universite de la Mediterranee, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France
    Phytother Res 18:990-5. 2004
    ..01, 0.1, 0.2, 0.3 microg/mL) and amphotericin B involved a decrease of the MIC 80% of amphotericin B...
  4. pmc Liposomal amphotericin B as a treatment for human leishmaniasis
    Manica Balasegaram
    Drugs for Neglected Diseases Initiative, Geneva, Switzerland
    Expert Opin Emerg Drugs 17:493-510. 2012
    ..Liposomal amphotericin B (LAMB), alone or in combination with other drugs, has been extensively studied as VL treatment, but data on ..
  5. pmc Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India
    Prabhat K Sinha
    Rajendra Memorial Research Institute of Medical Science, Patna, Bihar, India
    Am J Trop Med Hyg 83:357-64. 2010
    ..patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for the treatment of visceral leishmaniasis...
  6. ncbi Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence
    Koert Ritmeijer
    Public Health Department, Medecins Sans Frontieres, Amsterdam, The Netherlands
    Clin Infect Dis 53:e152-8. 2011
    ..high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human ..
  7. ncbi Combination therapy for visceral leishmaniasis
    Johan van Griensven
    Department of Clinical Sciences, Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium
    Lancet Infect Dis 10:184-94. 2010
    ..Whether combination therapy could indeed help delay resistance, and how this is best achieved, will only be known in the long term...
  8. ncbi Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
    Annemarie E Brouwer
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 363:1764-7. 2004
    ..In-vitro and animal studies lend support to the use of combinations of amphotericin B, flucytosine, and fluconazole for treatment of cryptococcosis...
  9. ncbi Drug resistance in Indian visceral leishmaniasis
    S Sundar
    Kala Azar Medical Research Centre, Banaras Hindu University, Varanasi, India
    Trop Med Int Health 6:849-54. 2001
    ..Despite several disadvantages, amphotericin B is the only drug available for use in these areas and should be used as first-line drug instead of Sb(v)...
  10. pmc Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial
    Joseph N Jarvis
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa
    AIDS 26:1105-13. 2012
    ..We performed a randomized controlled trial to determine whether addition of IFNγ to standard therapy increased the rate of clearance of cryptococcal infection in HIV-associated cryptococcal meningitis...
  11. ncbi High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial
    Tihana Bicanic
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 47:123-30. 2008
    The standard therapy for human immunodeficiency virus (HIV)-associated cryptococcal meningitis of amphotericin B (AmB; 0...
  12. pmc Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani
    Bidyut Purkait
    Department of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, Bihar, India
    Antimicrob Agents Chemother 56:1031-41. 2012
    The clinical value of amphotericin B, the mainstay therapy for visceral leishmaniasis in sodium antimony gluconate-nonresponsive zones of Bihar, India, is now threatened by the emergence of acquired drug resistance, and a comprehensive ..
  13. pmc Potential basis for amphotericin B resistance in Aspergillus terreus
    Gerhard Blum
    Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University, Innsbruck, Austria
    Antimicrob Agents Chemother 52:1553-5. 2008
    This study investigated the basis for intrinsic amphotericin B (AMB) resistance in Aspergillus terreus. The ergosterol content, cell wall composition, and lipid peroxidation level had no influence on AMB resistance...
  14. ncbi IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India
    Samiran Saha
    Infectious Disease and Immunology Division, Indian Institute of Chemical Biology, Kolkata, India
    J Immunol 179:5592-603. 2007
    ..the role of the differential decline of IL-10 and TGF-beta in response to sodium antimony gluconate (SAG) and amphotericin B (AmB), the therapeutic success of SAG and AmB in Indian VL, and the significance of IL-10 and TGF-beta in the ..
  15. ncbi Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India
    Prabhat K Sinha
    Rajendra Memorial Research Institute of Medical Science, Patna, Bihar
    Clin Infect Dis 53:e91-8. 2011
    ..To our knowledge, none have studied the efficacy of liposomal amphotericin B in VL-HIV coinfection...
  16. ncbi Oral miltefosine for Indian visceral leishmaniasis
    Shyam Sundar
    Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India
    N Engl J Med 347:1739-46. 2002
    ..We performed a clinical trial in India comparing miltefosine with the most effective standard treatment, amphotericin B.
  17. ncbi Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    Lancet 377:477-86. 2011
    ..Improved treatment approaches are needed for visceral leishmaniasis. We assessed the efficacy and safety of three potential short-course combination treatments compared with the standard monotherapy in India...
  18. ncbi Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda
    Y Mueller
    Medecins Sans Frontieres, Swiss Section, Rue de Lausanne 78, 1202 Geneva, Switzerland
    Ann Trop Med Parasitol 102:11-9. 2008
    ..was interrupted and all cases of visceral leishmaniasis presenting at the hospital could only be treated with amphotericin B deoxycholate (AmB)...
  19. pmc Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
    Raymond Omollo
    Drugs for Neglected Diseases initiative DNDi Africa, Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
    Trials 12:166. 2011
    ..such as miltefosine alone or in combinations including miltefosine, sodium stibogluconate (SSG) or liposomal amphotericin B. The aim of this trial is to identify regimen(s) which are sufficiently promising for future trials in East ..
  20. pmc Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)
    A Espinel-Ingroff
    VCU Medical Center, Richmond, Virginia, USA
    Antimicrob Agents Chemother 55:5150-4. 2011
    ..and amphotericin B. Two sets (CLSI/EUCAST broth microdilution) of available MICs were evaluated: those for A...
  21. ncbi Liposomal amphotericin B for the treatment of visceral leishmaniasis
    Caryn Bern
    Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 43:917-24. 2006
    During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL)...
  22. ncbi Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
    Thomas J Walsh
    National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 346:225-34. 2002
    Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative.
  23. ncbi Amphotericin B formulations: a comparative review of efficacy and toxicity
    Richard J Hamill
    Section of Infectious Diseases, Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, 2002 Holcombe Blvd, Houston, TX 77030 4211, USA
    Drugs 73:919-34. 2013
    ..of the increasing prevalence and changing microbiological spectrum of invasive fungal infections, some form of amphotericin B still provides the most reliable and broad spectrum therapeutic alternative...
  24. pmc A post-PKS oxidation of the amphotericin B skeleton predicted to be critical for channel formation is not required for potent antifungal activity
    Daniel S Palacios
    Roger Adams Laboratory, Department of Chemistry, University of Illinois at Urbana Champaign, Urbana, Illinois 61801, USA
    J Am Chem Soc 129:13804-5. 2007
  25. ncbi A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis
    Peter G Pappas
    Div of Infectious Diseases, University of Alabama at Birmingham Medical Center, 1900 University Blvd, THT 229, Birmingham, AL 35294 0006, USA
    Clin Infect Dis 48:1775-83. 2009
    ..Therapeutic options for the treatment of central nervous system cryptococcosis are limited, especially in resource-limited settings...
  26. ncbi Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans
    MaoMao An
    Department of Clinical Pharmacology, Chinese People s Liberation Army General Hospital, Beijing, PR China
    Int J Antimicrob Agents 33:258-63. 2009
    b>Amphotericin B (AmB) is the gold standard of antifungal treatment for the most severe invasive mycoses...
  27. pmc Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
    F S Nolte
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Antimicrob Agents Chemother 41:196-9. 1997
    ..albicans after receiving fluconazole prophylaxis (400 mg/day) and empiric amphotericin B therapy (0.5 mg/kg of body weight per day)...
  28. ncbi Amphotericin B: time for a new "gold standard"
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, TX, USA
    Clin Infect Dis 37:415-25. 2003
    When introduced in 1959, amphotericin B deoxycholate (AmBD) was clearly a life-saving drug. Randomized studies demonstrating its efficacy were not thought to be necessary, and it was granted indications for many invasive fungal infections...
  29. ncbi Single-dose liposomal amphotericin B for visceral leishmaniasis in India
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    N Engl J Med 362:504-12. 2010
    ..Liposomal amphotericin B is an effective treatment when administered in short courses...
  30. pmc Apoptosis induced by environmental stresses and amphotericin B in Candida albicans
    Andrew J Phillips
    Department of Molecular and Cell Biology, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD Aberdeen, Scotland
    Proc Natl Acad Sci U S A 100:14327-32. 2003
    ..albicans in response to environmental stresses (acetic acid and hydrogen peroxide) and an antifungal agent (amphotericin B). Exposure of C. albicans to 40-60 mM acetic acid, 5-10 mM hydrogen peroxide, or 4-8 microg...
  31. ncbi Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry
    David L Horn
    Div of Infectious Diseases, Thomas Jefferson University, Ste 210, 211 S 9th St, Philadelphia, PA 19107, USA
    Clin Infect Dis 48:1695-703. 2009
    ..Candidemia remains a major cause of morbidity and mortality in the health care setting, and the epidemiology of Candida infection is changing...
  32. ncbi Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections
    Marit D Moen
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 69:361-92. 2009
    Liposomal amphotericin B (AmBisome) is a lipid-associated formulation of the broad-spectrum polyene antifungal agent amphotericin B. It is active against clinically relevant yeasts and moulds, including Candida spp., Aspergillus spp...
  33. pmc Amphotericin primarily kills yeast by simply binding ergosterol
    Kaitlyn C Gray
    Department of Chemistry, Howard Hughes Medical Institute, University of Illinois at Urbana Champaign, Urbana, IL 61801, USA
    Proc Natl Acad Sci U S A 109:2234-9. 2012
    b>Amphotericin B (AmB) is a prototypical small molecule natural product that can form ion channels in living eukaryotic cells and has remained refractory to microbial resistance despite extensive clinical utilization in the treatment of ..
  34. ncbi Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation
    S L Kelly
    Krebs Institute for Biomolecular Research, Department of Molecular Biology and Biotechnology, Sheffield University, UK
    FEBS Lett 400:80-2. 1997
    ..is that an absence of ergosterol causes cross-resistance to the other major antifungal agent available, amphotericin B. The results also show that growth arrest after fluconazole treatment of C...
  35. ncbi Enhancement of amphotericin B activity against Candida albicans by superoxide radical
    Yuichi Okamoto
    Department of Oral and Maxillofacial Surgery II, Nippon Dental University, Niigata 951 8580, Japan
    Mycopathologia 158:9-15. 2004
    This study aimed to examine the involvement of oxidative damage in amphotericin B (AmB) activity against Candida albicans using the superoxide (O2-) generator paraquat (PQ)...
  36. ncbi Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial
    Jens U Ponikau
    Department of Otorhinolaryngology Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA
    J Allergy Clin Immunol 115:125-31. 2005
    ..Chronic rhinosinusitis (CRS) is one of the most common chronic diseases. Its etiology is unknown, and there is a paucity of effective medical treatments...
  37. pmc Role for cell density in antifungal drug resistance in Candida albicans biofilms
    Palani Perumal
    Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
    Antimicrob Agents Chemother 51:2454-63. 2007
    ..Planktonic yeast cells in RPMI 1640 were susceptible to azole-class drugs, amphotericin B, and caspofungin at 1 x 10(3) cells/ml (standard conditions) using the XTT [2,3-bis(2-methoxy-4-nitro-5-..
  38. pmc In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity
    Dhiraj Kumar
    Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India
    Antimicrob Agents Chemother 53:835-8. 2009
    ..results with respect to in vitro susceptibility to the antileishmanial drugs sodium antimony gluconate, amphotericin B, and Miltefosine, raising the possibility of cross-resistance mechanisms operating in the field isolates...
  39. ncbi Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL)
    A M Musa
    Department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
    Ann Trop Med Parasitol 99:563-9. 2005
    ..based on leishmaniasis candidate vaccines/BCG with SSG) are still experimental but treatment with liposomal amphotericin B (AmBisome) has already been found effective, albeit in a small number of patients...
  40. ncbi Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels
    Maciej Baginski
    Department of Pharmaceutical Technology and Biochemistry, Chemical Faculty, Technical University of Gdansk, Narutowicza St 11, 80 952 Gdansk, Poland
    Biochim Biophys Acta 1567:63-78. 2002
    b>Amphotericin B (AmB) is a very effective anti-fungal polyene macrolide antibiotic whose usage is limited by its toxicity...
  41. pmc Treatment of Mediterranean visceral leishmaniasis
    L Gradoni
    Laboratorio di Parassitologia, , Rome, Italy
    Bull World Health Organ 73:191-7. 1995
    ..Results of experimental and clinical trials on the efficacy and tolerability of liposomal amphotericin B in laboratory animals and in patients with ZVL are presented, as well as conclusions and recommendations on ..
  42. pmc Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin
    A Espinel-Ingroff
    Virginia Commonwealth University Medical Center, Richmond, VA 23298 0049, USA
    J Clin Microbiol 45:1811-20. 2007
    ..plain Mueller-Hinton [MH] agar), (ii) three incubation times (16 to 24, 48, and 72 h), and (iii) seven disks (amphotericin B and itraconazole 10-microg disks, voriconazole 1- and 10-microg disks, two sources of caspofungin 5-microg ..
  43. pmc Histoplasmosis: a clinical and laboratory update
    Carol A Kauffman
    Infectious Diseases Division, Department of Internal Medicine, Ann Arbor Veterans Affairs Healthcare System, University of Michigan Medical School, Ann Arbor, MI, USA
    Clin Microbiol Rev 20:115-32. 2007
    ..Classically, histoplasmosis has been treated with long courses of amphotericin B. Today, amphotericin B is rarely used except for severe infection and then only for a few weeks, followed by ..
  44. pmc Standardization of an experimental murine model of invasive pulmonary aspergillosis
    Donald C Sheppard
    McGill University, Department of Microbiology and Immunology, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 50:3501-3. 2006
    ..evaluated a murine model of aerosol infection in two independent laboratories and found a high level of both intra- and interlaboratory reproducibility of survival, fungal burden over time, and the efficacy of liposomal amphotericin B.
  45. ncbi A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis
    Leandro Ourives Neves
    Tropical Medicine Foundation of Amazonas, Manaus, Brazil
    An Bras Dermatol 86:1092-101. 2011
    ..Moreover, treatment outcome may depend on the causative species of Leishmania...
  46. pmc In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay
    Abdalla O A Ahmed
    Mycetoma Research Group, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Antimicrob Agents Chemother 48:2742-6. 2004
    Susceptibilities of Madurella mycetomatis against amphotericin B and itraconazole in vitro were determined by protocols based on NCCLS guidelines (visual reading) and a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-..
  47. pmc Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins
    D M Kuhn
    Division of Infectious Diseases, Department of Medicine, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio 44106, USA
    Antimicrob Agents Chemother 46:1773-80. 2002
    ..In addition to conventional agents, we determined if new antifungal agents (triazoles, amphotericin B lipid formulations, and echinocandins) have activities against Candida biofilms...
  48. ncbi Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study
    S Sundar
    Kala azar Medical Research Center, Banaras Hindu University, Varanasi, 221 005, India
    Clin Infect Dis 37:800-4. 2003
    Widespread antimony resistance renders conventional amphotericin B the only option for the treatment of visceral leishmaniasis (VL) in North Bihar, India. Because of its excellent safety profile, a large dose (7...
  49. ncbi Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B
    Sanyog Jain
    Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar Mohali, Punjab 160062, India
    Mol Pharm 9:2542-53. 2012
    b>Amphotericin B (AmB) loaded polymer lipid hybrid nanoparticles (AmB-PLNs) comprised of lecithin (anionic lipid) and gelatin (Type A, cationic below its isoelectric point 7.0-9...
  50. ncbi Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial
    Catherine Cordonnier
    Hematology Department, Henri Mondor Teaching Hospital, Assistance Publique Hôpitaux de Paris AP HP and Paris 12 University, Creteil, France
    Clin Infect Dis 48:1042-51. 2009
    ..Recent diagnostic improvements may ensure the early diagnosis of potentially invasive fungal disease. Reserving antifungals for this stage may achieve similar survival rates and reduce treatment toxicity and costs...
  51. ncbi Aspergillosis case-fatality rate: systematic review of the literature
    S J Lin
    Department of Pharmacy Administration, University of Illinois at Chicago, Chicago, IL, USA
    Clin Infect Dis 32:358-66. 2001
    ..7%) and for patients with central nervous system or disseminated aspergillosis (88.1%). Amphotericin B deoxycholate and lipid formulations of amphotericin B failed to prevent death in one-half to two-thirds of ..
  52. ncbi Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects
    B Eleazar Cohen
    Division of External Activities, National Institute of Allergy and Infectious Diseases, 6700B Rockledge Drive, Bethesda, MD 20982, USA
    J Membr Biol 238:1-20. 2010
    The formation of aqueous pores by the polyene antibiotic amphotericin B (AmB) is at the basis of its fungicidal and leishmanicidal action...
  53. pmc Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction
    Tsai Yu Lin
    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Cell Rep 5:895-908. 2013
    ..Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication...
  54. ncbi Effect of amphotericin B on parasitemia and survival of plasmodium berghei-infected mice
    Balasaheb Siraskar
    Department of Physiology, University of Tubingen, Tubingen, Germany
    Cell Physiol Biochem 26:347-54. 2010
    ..b>Amphotericin B has previously been shown to trigger suicidal erythrocyte death or eryptosis, which is characterized by cell ..
  55. ncbi Antifungal activity of amphotericin B conjugated to carbon nanotubes
    Monica Benincasa
    Department of Life Sciences, University of Trieste, Italy
    ACS Nano 5:199-208. 2011
    b>Amphotericin B (AMB) has long been considered the most effective drug in the treatment of serious invasive fungal infections...
  56. pmc Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy
    Andrew Kambugu
    Infectious Disease Institute, Makerere University, Kampala Uganda
    Clin Infect Dis 46:1694-701. 2008
    ..Cryptococcal meningitis (CM) is the proximate cause of death in 20%-30% of persons with acquired immunodeficiency syndrome in Africa...
  57. pmc Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
    Tansy Edwards
    MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, UK
    Trials 12:66. 2011
    ..AmBisome® is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use, either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has not been identified...
  58. pmc Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial
    S Sundar
    Kala Azar Medical Research Centre, Banaras Hindu University, Department of Medicine, Institute of Medical Sciences, Varanasi 211005, India
    BMJ 323:419-22. 2001
    To test short course, low dose liposomal amphotericin B as single or daily infusion treatment in Indian visceral leishmaniasis (kala-azar).
  59. pmc Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes
    Vijay Kumar Prajapati
    Infectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, India
    J Antimicrob Chemother 66:874-9. 2011
    This study describes the antileishmanial efficacy of the novel drug formulation of amphotericin B (AmB) attached to functionalized carbon nanotubes (f-CNTs) and compares it with AmB.
  60. ncbi Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study
    B E de Pauw
    University Hospital St Radboud, Nijmegen, The Netherlands
    Transpl Infect Dis 8:31-7. 2006
    Sensitivity analyses were incorporated in a Phase III study of caspofungin vs. liposomal amphotericin B as empirical antifungal therapy for febrile neutropenic patients to determine the impact of varying definitions of fever resolution on ..
  61. ncbi Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles
    Manoj Nahar
    Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr Hari Singh Gour University, Sagar, 470003, India
    Pharm Res 26:2588-98. 2009
    The objective of present work was to develop a mannose-anchored, engineered nanoparticulate system for efficient delivery of amphotericin B to macrophages. Furthermore, the effect of spacer on macrophage targeting was also evaluated.
  62. ncbi Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis
    Conrad K Muzoora
    Department of Medicine, Mbarara University Hospital, Plot 1 Hospital Road, P O Box 1410, Mbarara, Uganda
    J Infect 64:76-81. 2012
    ..To define more rapidly effective initial antifungal regimens sustainable in resource-constrained settings...
  63. ncbi Amphotericin B induces trehalose synthesis and simultaneously activates an antioxidant enzymatic response in Candida albicans
    Pilar Gónzalez-Párraga
    Area de Microbiologia, Facultad de Biologia, Universidad de Murcia, E 30071, Murcia, Spain
    Biochim Biophys Acta 1810:777-83. 2011
    ..To analyse this proposal, the susceptibility to Amphotericin B (AmB) of the C. albicans trehalose-deficient mutant tps1Δ/tps1Δ, was examined.
  64. ncbi Dependence of vacuole disruption and independence of potassium ion efflux in fungicidal activity induced by combination of amphotericin B and allicin against Saccharomyces cerevisiae
    Akira Ogita
    Department of Biology and Geosciences, Graduate School of Science, Osaka City University, Osaka, Japan
    J Antibiot (Tokyo) 63:689-92. 2010
    Allicin selectively enhances the fungicidal activity of amphotericin B (AmB). It also accelerates AmB-induced vacuole disruption but does not affect AmB-induced potassium ion efflux in Saccharomyces cerevisiae and Candida albicans...
  65. pmc Proteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B
    Poonam Gautam
    Innate Immunity, National Institute for Research in Reproductive Health, JM Street, Parel, Mumbai, India
    Antimicrob Agents Chemother 52:4220-7. 2008
    b>Amphotericin B (AMB) is the most widely used polyene antifungal drug for the treatment of systemic fungal infections, including invasive aspergillosis...
  66. pmc Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides
    E J Helmerhorst
    Department of Oral Biochemistry, Vrije Universiteit, Amsterdam, The Netherlands
    Antimicrob Agents Chemother 43:702-4. 1999
    ..5, a designed histatin analog designated dhvar4, and a peptide from frog skin, PGLa, are active against amphotericin B-resistant Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-..
  67. ncbi Survival time of HIV-infected patients with cryptococcal meningitis
    Suthat Chottanapund
    Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    J Med Assoc Thai 90:2104-11. 2007
    ..To study survival time and risk factors of mortality among HIV-infected patients who had cryptococcal meningitis...
  68. ncbi Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis
    Fenna A Ebbens
    Department of Otorhinolaryngology, Head and Neck Surgery, Academic Medical Center, Amsterdam, The Netherlands
    J Allergy Clin Immunol 118:1149-56. 2006
    ..On the basis of this hypothesis, intranasal treatment with amphotericin B should benefit patients with CRS. Data from 2 uncontrolled and 2 controlled trials are conflicting, however.
  69. ncbi Injectable paromomycin for Visceral leishmaniasis in India
    Shyam Sundar
    Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
    N Engl J Med 356:2571-81. 2007
    ..Safe, effective, and affordable new therapies are needed. We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care in Bihar, India.
  70. pmc Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene
    Jeniel E Nett
    Department of Medicine, University of Wisconsin, 600 Highland Ave, H4 572 Clinical Sciences Center, Madison, WI 53792, USA
    Antimicrob Agents Chemother 54:3505-8. 2010
    ..Reduction of FKS1 expression rendered biofilms more susceptible to amphotericin B, anidulafungin, and flucytosine...
  71. ncbi Amphotericin B: spectrum and resistance
    David Ellis
    Mycology Unit, Women s and Children s Hospital, North Adelaide 5006, Australia
    J Antimicrob Chemother 49:7-10. 2002
    b>Amphotericin B is a polyene macrolide antibiotic derived from the actinomycete Streptomyces nodosus...
  72. ncbi A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia
    Johan A Maertens
    Acute Leukemia and Stem Cell Transplantation Unit, Department of Hematology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium
    Pediatr Infect Dis J 29:415-20. 2010
    ..However, little is known about the role of echinocandins and liposomal amphotericin B (L-AmB) for empiric antifungal therapy in pediatric patients.
  73. ncbi Enhancement of the fungicidal activity of amphotericin B by allicin, an allyl-sulfur compound from garlic, against the yeast Saccharomyces cerevisiae as a model system
    Akira Ogita
    Institute for Health and Sport Sciences, Osaka City University, 3 3 138 Sugimo to, Sumiyoshi ku, Osaka 558 8585, Japan
    Planta Med 72:1247-50. 2006
    b>Amphotericin B (AmB) is a representative antibiotic for the control of serious fungal infections, and its fungicidal activity was greatly enhanced by allicin, an allyl-sulfur compound from garlic...
  74. ncbi The vacuole-targeting fungicidal activity of amphotericin B against the pathogenic fungus Candida albicans and its enhancement by allicin
    Hasibagan Borjihan
    Department of Biology and Geosciences, Graduate School of Science, Osaka City University, Sumiyoshi ku, Osaka, Japan
    J Antibiot (Tokyo) 62:691-7. 2009
    In this study, the vacuole disruptive activity was evaluated as a cause of amphotericin B (AmB) lethality against the pathogenic fungus Candida albicans in terms of its enhancement by allicin, an allyl-sulfur compound from garlic...
  75. pmc Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy
    Matthew K Schinabeck
    Center for Medical Mycology and Mycology Reference Laboratory, Department of Dermatology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio 44106, USA
    Antimicrob Agents Chemother 48:1727-32. 2004
    ..albicans biofilms and show that antifungal lock therapy with liposomal amphotericin B is an effective treatment strategy for these infections...
  76. ncbi Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B
    Patricia Escobar
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Acta Trop 81:151-7. 2002
    ..5-37.1 microM against amastigotes. Amphotericin B deoxycholate was used as the standard drug and gave submicromolar ED(50) values in all assays; L...
  77. ncbi Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy
    S M Trifilio
    Department of Pharmacy, Division of Hematology Oncology, Northwestern Memorial Hospital, Chicago, IL, USA
    Bone Marrow Transplant 39:425-9. 2007
    ..b>Amphotericin B was the most commonly prescribed anti-fungal therapy. Overall mortality was 73%...
  78. pmc Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms
    G Ramage
    Department of Microbiology, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, Texas 78245, USA
    Antimicrob Agents Chemother 45:2475-9. 2001
    ..albicans strains grown as biofilms against amphotericin B and fluconazole and the increased resistance of C...
  79. ncbi Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
    Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis.
  80. ncbi Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis
    S Sundar
    Kala azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    Am J Trop Med Hyg 80:700-3. 2009
    b>Amphotericin B deoxycholate is used as a first-line drug for visceral leishmaniasis (VL) in India. Its major drawbacks are prolonged hospitalization of treated patients and toxicity...
  81. ncbi Amphotericin B nephrotoxicity
    Gilbert Deray
    Nephrology Department, Pitie Salpetriere Hospital, Boulevard de l Hopital, Paris 750013, France
    J Antimicrob Chemother 49:37-41. 2002
    The use of amphotericin B limited by dose-dependent nephrotoxicity...
  82. ncbi Apoptosis in Candida biofilms exposed to amphotericin B
    Rawya S Al-Dhaheri
    Division of Infection and Immunity, Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK
    J Med Microbiol 59:149-57. 2010
    ..the existence of persisters and apoptosis in Candida biofilms subjected to different concentrations of amphotericin B. Fluorescein diacetate staining revealed the presence of persisters in biofilms of one of two strains of ..
  83. ncbi Unresponsiveness to AmBisome in some Sudanese patients with kala-azar
    Marius Mueller
    Medecins Sans Frontieres, Plantage Middenlaan 14, 1018 DD Amsterdam, The Netherlands
    Trans R Soc Trop Med Hyg 101:19-24. 2007
    ..are currently registered for visceral leishmaniasis: sodium stibogluconate (SSG) as first line and liposomal amphotericin B (AmBisome) as second line...
  84. pmc Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study
    Francoise Dromer
    Unité de Mycologie Moléculaire, Centre National de Référence Mycologie et Antifongiques, CNRS URA3042, Institut Pasteur, Paris, France
    PLoS Med 4:e21. 2007
    ....
  85. ncbi Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient
    Mikkel Krogh-Madsen
    Department of Clinical Microbiology, H S Hvidovre Hospital, Hvidovre, Denmark
    Clin Infect Dis 42:938-44. 2006
    Consecutive Candida glabrata isolates recovered from a patient in an intensive care unit were resistant to amphotericin B (minimum inhibitory concentration, up to 32 mu g/mL; determined by Etest [AB Biodisk])...
  86. ncbi Overview of the lipid formulations of amphotericin B
    Bertrand Dupont
    Group Hospitalier Necker Enfants Malades, 149 rue de Sevres, Paris Cedex 15, 75743, France
    J Antimicrob Chemother 49:31-6. 2002
    ..b>Amphotericin B has a broad spectrum and has remained the drug of choice for life-threatening invasive fungal infections...
  87. ncbi Mortality and costs of acute renal failure associated with amphotericin B therapy
    D W Bates
    Division of General Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 32:686-93. 2001
    To assess the mortality and resource utilization that results from acute renal failure associated with amphotericin B therapy, 707 adult admissions in which parenteral amphotericin B therapy was given were studied at a tertiary-care ..
  88. ncbi Management of Candida species infections in critically ill patients
    Philippe Eggimann
    Medical Clinic II and Intensive Care Unit, and the Infection Control Programme, Department of Internal Medicine, University of Geneva Hospitals, Geneva, Switzerland
    Lancet Infect Dis 3:772-85. 2003
    ..Among critically ill patients, azole prophylaxis is effective and is not associated with acquisition of resistance; it must be restricted to highly selected groups of patients at high risk only...
  89. ncbi New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi, India
    Clin Infect Dis 47:1000-6. 2008
    ..of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine.
  90. ncbi SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs
    R H Muller
    Department of Pharmaceutical Technology, Biotechnology and Quality Management, Free University Berlin, Kelchstrasse 31, 12169 Berlin, Germany
    Int J Pharm 269:293-302. 2004
    ..g. amphotericin B. For achieving this, up to now organic solvents were required...
  91. ncbi Potentiation of antifungal activity of amphotericin B by essential oil from Cinnamomum cassia
    R Giordani
    Laboratoire de Botanique, Cryptogamie et Biologie Cellulaire, Faculte de Pharmacie, Universite de la Mediterranee, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France
    Phytother Res 20:58-61. 2006
    The antifungal activity of the essential oil from Cinnamomum cassia, alone or combined with amphotericin B, a drug widely used for most indications despite side-effects was investigated...
  92. pmc Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
    M E Klepser
    College of Pharmacy, University of Iowa, Iowa City 52242 1112, USA
    Antimicrob Agents Chemother 41:1392-5. 1997
    Time-kill curves were determined for three isolates of Candida albicans tested against fluconazole and amphotericin B at multiples of the MIC...
  93. ncbi A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients
    Raleigh Bowden
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Infect Dis 35:359-66. 2002
    We report a randomized, double-blind, multicenter trial in which amphotericin B colloidal dispersion (ABCD [Amphotec]; 6 mg/kg/day) was compared with amphotericin B (AmB; 1.0-1...
  94. ncbi Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole
    Annette W Fothergill
    University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Med Mycol 47:41-3. 2009
    ..we tested 160 clinical isolates against amphotericin B, itraconazole, posaconazole, and voriconazole in a head-to-head comparison...
  95. ncbi Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group
    F Laguna
    Servicio de Enfermedades Infecciosas, Centro Nacional de Investigacion Clinica, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 13:1063-9. 1999
    ..Visceral leishmaniasis is common in patients with HIV infection living in endemic areas, but the most effective and safe treatment remains unknown...
  96. ncbi Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles
    Waree Tiyaboonchai
    Department of Pharmaceutical Technology, Naresuan University, Pitsanulok 65000, Thailand
    Int J Pharm 329:142-9. 2007
    A new nanoparticulate delivery system for amphotericin B (AmB) has been developed by means of the polyelectrolyte complexation technique...
  97. ncbi Poor efficacy of amphotericin B-based therapy in CNS aspergillosis
    Stefan Schwartz
    Medizinische Klinik III, Charite Campus Benjamin Franklin, Freie Universitat, Berlin, Germany
    Mycoses 50:196-200. 2007
    ..assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2)...
  98. pmc Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation
    S Rama Iñiguez
    Departamento de Parasitologia, Facultad de Farmacia, Universidad Complutense, Plaza de Ramón y Cajal s n, Ciudad Universitaria, 28040 Madrid, Spain
    Antimicrob Agents Chemother 50:1195-201. 2006
    ..in the golden Syrian hamster Mesocricetus auratus infected with Leishmania infantum and treated with amphotericin B (AMB) formulated in microspheres made of human serum albumin (HSA)...
  99. ncbi Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections
    Kristina Sachs-Barrable
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
    Adv Drug Deliv Rev 60:692-701. 2008
    ..b>Amphotericin B (AmpB) is one example of a well established, highly efficacious drug that has a 50 year history of intravenous ..
  100. ncbi A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT
    H Hebart
    Department of Hematology Oncology, Internal Medicine II, Eberhard Karls University, Tuebingen, Germany
    Bone Marrow Transplant 43:553-61. 2009
    We compared the efficacy and safety of empirical plus PCR-based vs empirical liposomal amphotericin B treatment after Allo-SCT...
  101. ncbi Combinations of antifungal agents in therapy--what value are they?
    Manuel Cuenca-Estrella
    Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Madrid, Spain
    J Antimicrob Chemother 54:854-69. 2004
    ..However, combination therapy could be an alternative to monotherapy for patients with invasive infections that are difficult to treat, such as those due to multi-resistant species and for those who fail to respond to standard treatment...

Research Grants64

  1. Triazole hypersensitivity in Candida albicans
    Neeraj Chauhan; Fiscal Year: 2009
    ..the wild type levels of sensitivity to other antifungals such as miconazole and ketoconazole (imidazoles), amphotericin B, caspofungin, 5-FC, and a variety of other inhibitors such as Congo red, calcofluor white, hygromycin and ..
  2. Genetic and Evolutionary Basis of Fungal Drug Resistance
    Zhenglong Gu; Fiscal Year: 2013
    ..Surprisingly, the same mutation confers YJM789 drug resistance to another antifungal drug (Amphotericin B, AmB), which is a quantitative trait also determined by other genetic factors...
  3. Manipulation of Host Angiogenesis as a Therapeutic Strategy against Invasive Pulm
    Dimitrios P Kontoyiannis; Fiscal Year: 2010
    ..of treating IA with pro-angiogenic growth factors, alone or in combination with the antifungal drug amphotericin B (AMB)...
  4. Novel Antifungal Therapeutic Approaches
    Joseph Heitman; Fiscal Year: 2012
    ..Antifungal agents were limited to amphotericin B, flucytosine, and azoles, but now the candins, second-generation azoles, and lipid based amphotericin ..
  5. Development of novel therapeutics for a neglected tropical disease leishmaniasis
    ABHAY R contact SATOSKAR; Fiscal Year: 2010
    ..Antimonials (Glucantime(tm) and Pentostam(tm)), amphotericin B, and miltefosine are used to treat leishmaniasis...
  6. Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental Outcomes
    Daniel K Benjamin; Fiscal Year: 2012
    ..and Walsh) of other antifungal agents in the nursery including pharmacokinetic and pharmacodynamic studies of amphotericin B, liposomal amphotericin B products, anidulafungin, and micafungin This research will show that fluconazole ..
  7. Discovering a Combination Therapeutic Approach to Use in the Treatment of Cryptoc
    Mitchell W Mutz; Fiscal Year: 2013
    ..Lack of access to the recommended first-line therapeutic combination of amphotericin B/flucytosine (AmB/flucytosine) is a key component of the high mortality rate in the developing world...
  8. Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
    Glen S Kwon; Fiscal Year: 2013
    ..Towards enabling in vivo PD studies, we made exciting progress in combination delivery (co-delivery) of amphotericin B (AmB) with other antifungal agents via self-assembled polymers, fulfilling requirements in solubility, safety, ..
  9. THERAPY AGAINST RECALCITRANT C. albicans INFECTION
    Thomas A Dahl; Fiscal Year: 2012
    ..Our in vitro studies showed that amphotericin B or miconazole applied even at high, topical concentrations are not effective against a mature biofilm of C...
  10. Trial for the Optimal Timing of HIV Therapy after Cryptococcal Meningitis
    David R Boulware; Fiscal Year: 2013
    ..The optimal time to start HIV therapy is unknown. This is a definitive strategy trial to determine if early initiation of HIV therapy while hospitalized results in superior long term survival. ..
  11. Myocotic Ulcer Treatment Trial
    Thomas M Lietman; Fiscal Year: 2013
    ..Fungal ulcers tend to have very poor outcomes with the commonly used treatments, natamycin and amphotericin B. There has been only a single randomized trial of anti-fungal therapy for mycotic keratitis, and no new ocular ..
  12. A Computer Modeling Approach to Create an Antifungal to Improve the Treatment of
    Mitchell W Mutz; Fiscal Year: 2013
    ..For decades, Amphotericin B (AmB) has been the mainstay therapeutic for CM...
  13. Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis
    David R Boulware; Fiscal Year: 2013
    ..3) We will determine risk factors for poor neurocognitive outcomes in persons with cryptococcosis. ..
  14. Multi-center studies to improve diagnosis and treatment of pediatric candidiasis
    Theoklis Zaoutis; Fiscal Year: 2013
    ..of pediatric invasive candidiasis to compare the effectiveness of current pediatric antifungal treatments (amphotericin B, triazoles, and echinocandins)...
  15. Natural Product Treatments for Leishmaniasis
    Dennis E Kyle; Fiscal Year: 2013
    ..is most often treated by parenteral administration of toxic drugs such as pentavalent antimonials and amphotericin B, and drug resistance is becoming a problem...
  16. Targeting DHFR to Design Antimicrobial Agents
    Amy C Anderson; Fiscal Year: 2012
    ..glabrata is inherently resistant to several of the available antifungal therapeutics, including amphotericin B and the azole compounds. Therapeutics to treat C. glabrata infections are critically necessary...
  17. UV, CD, and NMR studies of Amphotericin B in nanoscale discoidal lipid bilayers
    THOMAS MICHAEL ANDERSON; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The clinically vital, but severely nephrotoxic, antifungal Amphotericin B has a unique mechanism of action;rather than bind to a macromolecular target, it self-assembles into membrane ion channels in ..
  18. THE YEAST ERGOSTEROL PATHWAY
    Martin Bard; Fiscal Year: 2007
    ..Two of the most widely used antifungal classes, the polyenes (amphotericin B) target plasma membrane-bound sterols and the azoles (fluconazole, and itraconazole) target the cytochrome ..
  19. Amphotericin B Analogs
    Charles Hutchinson; Fiscal Year: 2009
    ..b>Amphotericin B (AMB) continues to be an important drug for invasive aspergillosis, candidemia, mucormycosis, fusariosis and ..
  20. YEAST ERGOSTEROL PATHWAY--NEW ANTIFUNGAL TARGET SITES
    Martin Bard; Fiscal Year: 1999
    ..Two of the most widely used antifungal classes, the polyenes (amphotericin B) target plasma membrane-bound sterols and the new classes of azoles (ketoconazole, fluconazole, and ..
  21. Determining the Architectures and Activities of Polyketide Synthase Modules
    ADRIAN TRISTAN KEATINGE-CLAY; Fiscal Year: 2013
    ....
  22. ANTI-AIDS NUCLEOSIDE CONJUGATES OF ETHER PHOSPHOLIPIDS
    CHUNG HONG; Fiscal Year: 1992
    ..sonicated solution of the proposed conjugates in which the anti-HIV agents include AL-721, rifabutin, and amphotericin B methyl ester...
  23. Antifungal drugs: Beta(1,6)-glucan synthesis inhibitors
    Claude Selitrennikoff; Fiscal Year: 2003
    ..Currently-available drugs include polyenes (e.g., amphotericin B) that complex with fungal-membrane ergosterol, a number of azoles and allylamines that inhibit steps in the ..
  24. The glyoxylate cycle as a new target for antifungals
    Claude Selitrennikoff; Fiscal Year: 2003
    ..Currently-available drugs include polyenes (e.g., amphotericin B) that complex with fungal-membrane ergosterol, a number of azoles and allylamines that inhibit steps in the ..
  25. Antifungal Drug Susceptibility of Cryptococcus neoformans
    Robert Larsen; Fiscal Year: 2009
    ..Presently selection of which anti-fungal agent (amphotericin B, fluconazole or the two combined), the dose and the duration of therapy are guided by clinical judgment from ..
  26. A NOVEL TARGET FOR THE DEVELOPMENT OF ANTIFUNGAL AGENTS
    Corey Nislow; Fiscal Year: 2001
    ..In addition, the two accepted therapies, amphotericin B and the azoles, have limited effectiveness and toxic side-effects...
  27. ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS
    GLEN KWON; Fiscal Year: 2002
    ..This concept will be explored for amphotericin B (AmB), the key drug for systemic fungal diseases...
  28. GENETIC & MOLECULAR BIOLOGY OF VIRULENCE IN C NEOFORMANS
    John Perfect; Fiscal Year: 2004
    Cryptococcus neoformans causes a life threatening meningoencephalitis and despite treatments with amphotericin B and newer triazoles the management of this infection remains problematic...
  29. INTERACTION OF H CAPSULATUM WITH ALVEOLAR MACROPHAGE
    Simon Newman; Fiscal Year: 1999
    ..with disseminated histoplasmosis have a high rate of relapse even after apparently successful therapy with amphotericin B. The pulmonary alveolar monocyte/macrophage (AM) is the first line of defense following inoculation of Hc into ..
  30. Actin-binding proteins as novel antifungal targets
    Corey Nislow; Fiscal Year: 2001
    ..The two accepted therapies, amphotericin B and the azoies, have limited effectiveness and toxic side-effects...
  31. DRUG-INDUCED SHIVERING--EFFECTS OF A NURSING MEASURE
    BARBARA HOLTZCLAW; Fiscal Year: 1990
    This experimental study tests a nursing intervention to reduce drug-induced shivering related to amphotericin B. Predictors and consequences of shivering will be sought from patient responses and physiological correlates...
  32. Synthesis and Study of Amphotericin B Derivatives
    Martin D Burke; Fiscal Year: 2013
    ....
  33. Inhalable amphotericin B nanodisk therapy for pulmonary aspergillosis
    Trudy Forte; Fiscal Year: 2005
    ..The current first-line treatment for aspergillosis is amphotericin B (ampB) but it is both highly nephrotoxic and insoluble...
  34. HUMAN NEUTROPHIL RC-RECEPTOR-MEDIATED PHAGOCYTOSIS
    Hattie Gresham; Fiscal Year: 1990
    ..Certain agents (aliphatic alcohols, amphotericin B, tumor-promoting phorbol esters, and chemotactic peptides) which modify the microenvironment of the PMN Fc ..
  35. Development of a low cost formulation of amphotericin B
    SHING CHANG; Fiscal Year: 2009
    ..and simply reconstituted formulation as an alternative for the current reference treatment, liposomal amphotericin B (AmB). The project is based on use of narrow molecular weight polymers to which AmB is bound...
  36. Molecular Umbrella-Amphotericin B Conjugates
    Steven L Regen; Fiscal Year: 2013
    ..will test this hypothesis, rigorously, using a variety of conjugates made from molecular umbrellas and amphotericin B (AmB) in (i) model membrane studies, (ii) cytotoxicity, hemolytic and antifungal measurements, and (iii) in ..
  37. CHEMICAL STUDIES OF NOVEL SULFUR CONTAINING ANTIBIOTICS
    Eloy Rodriguez; Fiscal Year: 1993
    ..and UV radiation against Candida albicans, and Aspergillus fumigatus at concentrations comparable to those of amphotericin B. The compounds are also active against nematodes and a variety of retroviruses...
  38. Inhibitors of transcription of fungal glucan synthase
    Claude Selitrennikoff; Fiscal Year: 2003
    ..Current treatments for fungal infections are limited by few therapeutic options; these include amphotericin B, which interacts with membrane sterols, and a variety of azoles and allylamines that inhibit membrane sterol ..
  39. ANTISENSE INHIBITION OF FUNGAL GROWTH
    Carol Enderlin; Fiscal Year: 1993
    ..We expect that antisense oligonucleotides may be important, novel therapeutic agents directed specifically against fungi...
  40. ENDOGENOUS FUNGAL ENDOPHTHALMITIS
    Dan Jones; Fiscal Year: 1980
    ..Intravenous amphotericin B, intravenous amphotericin B methyl ester, and oral ketoconazole reduce the severity of C...
  41. STEREOSELECTIVE SYNTHESIS OF CYCLIC ETHERS
    P Evans; Fiscal Year: 2002
    ..The gamberic acids A-D represent the most potent antifungal agents known, with activity exceeding that of amphotericin B by over three orders of magnitude, making them extremely important targets.
  42. SCREENING OF MARINE ORGANISMS FOR ANTIFUNGAL ACTIVITY
    Claude Selitrennikoff; Fiscal Year: 1999
    ..Current treatments for fungal infections are limited to a few therapeutic options, primarily amphotericin B which interacts with membrane sterols and azoles which inhibit membrane-sterol biosynthesis...
  43. MECHANISMS OF AMPHOTERICIN B NEPHROTOXICITY
    Robert Branch; Fiscal Year: 1999
    ..This proposal is a request for continued support for studies using amphotericin B as a model of a drug whose clinical utility as an anti- fungal and parasitic agent is curtailed by its ..
  44. A TARGETED AMPHOTERICIN B PRODRUG FOR ANTIFUNGAL THERAPY
    SEAN O MALLEY; Fiscal Year: 2000
    ..An antibody-directed enzyme prodrug activation system will be developed for activation of the novel prodrug of amphotericin B prepared in Phase I research...
  45. Oral AmB for the treatment of fungal infection
    Raphael Mannino; Fiscal Year: 2003
    ..The SBIR Phase I advanced the development of a new formulation of amphotericin B (AmB) that has low toxicity and allows the oral delivery of AmB...
  46. IDENTIFYING TOR'S MODE OF ACTION
    Siegfried Detke; Fiscal Year: 2002
    ..TOR, an atypical multi drug resistance factor, elicits resistance to toxic nucleoside as well as to Pentostam, Amphotericin B and a number of other structurally unrelated compounds...
  47. NOVEL AMPHOTERICIN B NANOPARTICLES FOR SYSTEMIC MYCOSIS
    James Woiszwillo; Fiscal Year: 2001
    ..this technology by optimizing the formulation to maximize incorporation efficiency, stability and safety of amphotericin B. Amphotericin B is the only drug effective against severe systemic fungal infections in immunocompromised ..
  48. A NOVEL SCREEN FOR INHIBITORS OF FUNGAL GPI-ANCHORING
    Claude Selitrennikoff; Fiscal Year: 2002
    ..Current treatments include Amphotericin B and a variety of azoles that inhibit membrane-sterol biosynthesis...
  49. COCHLEATE DRUG DELIVERY AGAINST FUNGAL INFECTIONS
    Leila Zarif; Fiscal Year: 1999
    ..The present application will focus on investigating the properties of Amphotericin B cochleate formulations on the growth of the microorganisms in vitro and in vivo...
  50. Novel Antimicrobials: Salivary MUC7 Peptides
    LIBUSE BOBEK; Fiscal Year: 2007
    ..Altogether, these efforts attempt to move the MUC7 peptides toward the long-range goal of clinical application. ..
  51. Synthetic Reactions Catalyzed by Transition Metals
    Ei ichi Negishi; Fiscal Year: 2010
    ..Being considered for this purpose are discodermolide, hennoxazole A, zincophorin, roselipins, apoptolidin, nafuredin, caIlystatin A, milbemycin p3, calyculin A, and amphotericin B.
  52. Molecular Umbrellas as Membrane Transporters
    STEVEN REGEN; Fiscal Year: 2009
    ..phospholipid bilayers, (ii) testing the feasibility of creating molecular umbrella conjugates of Amphotericin B that exhibit high critical micelle concentrations, high hydrolytic stability and high membrane selectivity, ..
  53. GENETIC TRANSFER IN MAMMALIAN SOMATIC CELLS
    SOL GOODGAL; Fiscal Year: 1980
    ..this end we have screened a large number of both spontaneous and induced mutants for ouabain resistance, amphotericin B resistance, and growth in minimal medium (auxotrophic markers)...
  54. HOST IMMUNOREGULATION OF ANTILEISHMANIAL CHEMOTHERAPY
    Henry Murray; Fiscal Year: 2005
    ..therapeutic strategies in kala-azar, the two logical complementary approaches are (a) new drug development (amphotericin B (AmB), miltefosine) and (b) identification of immunologic mechanisms which can be regulated and translated ..
  55. Host Immunoregulation of Response to Antileishmanial Chemotherapy
    Henry Murray; Fiscal Year: 2007
    ..abstract_text> ..
  56. Novel Antifungal Strategies for Lethal Mucormycosis
    Ashraf Ibrahim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  57. Treatment of Fungal Infections with ATAK Cells
    Ashraf Ibrahim; Fiscal Year: 2004
    ..Furthermore, the genetic construct targeting ATAK cells to Candida can easily be adapted to any other pathogen against which a MAb has been raised. ..
  58. QUALITY OF LIFE AND RELATIONSHIPS AFTER BMT
    John Wingard; Fiscal Year: 2001
    ..This information is essential to subsequent planning and implementation of relevant, well-aimed interventions to minimize psychosocial disruption and enhance growth in future BMT recipients and their loved ones. ..
  59. Calcineurin and Aspergillus fumigatus Pathogenesis
    WILLIAM STEINBACH; Fiscal Year: 2008
    ..I will also test the non-immunosuppressive calcineurin inhibitor analogs to decrease the total level of immunosuppression and therefore increase the overall antifungal efficacy of exploiting the calcineurin pathway. ..
  60. Prevention/diagnosis/fungal infections/transplantation
    Barbara Alexander; Fiscal Year: 2005
    ..These aims will be met through a series of clinical trials. The safety and tolerability of inhaled Amphotericin B Lipid Complex (ABLC) will be determined in the allogeneic BMT population through a non-randomized open-label ..
  61. Transplant Associated Infection Surveillance Network
    Peter Pappas; Fiscal Year: 2008
    ..Finally, the establishment of a bank will be invaluable in the development and validation of newer diagnostic assays. ..
  62. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2008
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..